Price
Financials
Consolidated, Rs crore| Mar 2025 | Jun 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|
| Sales | 48.93 | 33.30 | 35.58 | 50.89 | 87.56 |
| Expenses | 31.74 | 27.06 | 23.30 | 35.60 | 71.97 |
| Operating Profit | 17.19 | 6.24 | 12.28 | 15.29 | 15.59 |
| OPM % | 35.13% | 18.74% | 34.51% | 30.05% | 17.80% |
| Other Income | 0.04 | 0.01 | 0.20 | 0.01 | 0.06 |
| Interest | 0.91 | 0.82 | 1.51 | 0.57 | 0.92 |
| Depreciation | 0.83 | 0.43 | 0.35 | 0.29 | 1.07 |
| Profit before tax | 15.49 | 5.00 | 10.62 | 14.44 | 13.66 |
| Tax % | -7.49% | 29.20% | 51.41% | 23.34% | 39.39% |
| Net Profit | 16.65 | 3.55 | 5.15 | 11.07 | 8.28 |
| EPS in Rs | 0.42 | 0.09 | 0.10 | 0.20 | 0.13 |
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Sales | 120 | 172 |
| Expenses | 88 | 124 |
| Operating Profit | 32 | 48 |
| OPM % | 27% | 28% |
| Other Income | 0 | 0 |
| Interest | 4 | 4 |
| Depreciation | 2 | 2 |
| Profit before tax | 27 | 43 |
| Tax % | 24% | 32% |
| Net Profit | 21 | 29 |
| EPS in Rs | 0.51 | 0.54 |
| Dividend Payout % | 0% | 0% |
| 10 Years | 5 Years | 3 Years | TTM | 1 Year | Last Year | |
|---|---|---|---|---|---|---|
| Compounded Sales Growth | % | % | % | 43% | ||
| Compounded Profit Growth | % | % | % | 39% | ||
| Stock Price CAGR | % | % | % | 176% | ||
| Return on Equity | % | % | % | 18% |
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Equity Capital | 40 | 53 |
| Reserves | 41 | 177 |
| Borrowings | 67 | 44 |
| Other Liabilities | 34 | 100 |
| Total Liabilities | 181 | 374 |
| Fixed Assets | 23 | 58 |
| CWIP | 0 | 0 |
| Investments | 1 | 1 |
| Other Assets | 158 | 315 |
| Total Assets | 181 | 374 |
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Cash from Operating Activity | -22 | -59 |
| Cash from Investing Activity | 2 | -36 |
| Cash from Financing Activity | 19 | 118 |
| Net Cash Flow | -1 | 23 |
| Free Cash Flow | -19 | -95 |
| CFO/OP | -85% | -114% |
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Debtor Days | 228 | 220 |
| Inventory Days | 246 | 393 |
| Days Payable | 96 | 147 |
| Cash Conversion Cycle | 377 | 467 |
| Working Capital Days | 292 | 417 |
| ROCE % | 21% |
| Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|
| Promoters | 52.68% | 52.68% | 52.68% | 52.68% |
| FIIs | 0.00% | 0.23% | 0.32% | 1.67% |
| DIIs | 2.83% | 4.49% | 4.60% | 1.23% |
| Public | 44.49% | 42.60% | 42.40% | 44.43% |
| No. of Shareholders | 12,464 | 11,412 | 12,484 | 34,671 |
Fundamentals
Market Cap₹ 1,928 Cr.
Current Price₹ 36.4
Stock P/E61.0
Book Value₹ 4.33
ROCE20.8 %
ROE18.4 %
Dividend Yield0.00 %
Face Value₹ 2.00
Compounded Sales Growth (TTM)43%
Compounded Profit Growth (TTM)39%
Consolidated figures.
Ownership
Promoter holding52.68%
Computed by MarketFriction from the consolidated statements. Returns use average balances.
Not enough history to build valuation bands (needs two years of profits and prices).
| Period | AHCL | Nifty 50 | Difference |
|---|---|---|---|
| 1 week | +14.7% | -2.8% | +17.5 pts |
| 1 month | +112.1% | -6.8% | +118.9 pts |
| 3 months | +107.1% | -7.6% | +114.7 pts |
| 6 months | +195.0% | +0.4% | +194.6 pts |
| 1 year | +145.6% | -9.9% | +155.5 pts |
Red flags
| look | On NSE surveillance On NSE surveillance: ASM long-term |
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.
Latest quarter
Jun 2026Sales ₹88 Cr +78.9% vs Mar 2025.
Net profit ₹8 Cr -50.3%.
Activity
Compare| Company | Mcap (Cr) | P/E | ROCE |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | 447,476 | 35.4 | 20.5 % |
| Divis Laboratories Ltd | 250,363 | 84.0 | 22.0 % |
| Torrent Pharmaceuticals Ltd | 186,152 | 83.4 | 15.2 % |
| Zydus Lifesciences Ltd | 119,750 | 24.6 | 21.1 % |
| Cipla Ltd | 111,430 | 31.1 | 15.5 % |
| Laurus Labs Ltd | 106,928 | 97.8 | 17.8 % |
| Mankind Pharma Ltd | 105,120 | 49.3 | 13.5 % |
| Dr Reddys Laboratories Ltd | 104,494 | 32.4 | 13.0 % |
| Aurobindo Pharma Ltd | 97,682 | 25.8 | 12.9 % |
| Lupin Ltd | 93,840 | 15.8 | 29.9 % |
| Glenmark Pharmaceuticals Ltd | 68,905 | 22.1 | 39.8 % |
| Alkem Laboratories Ltd | 62,772 | 27.6 | 21.2 % |
| Biocon Ltd | 61,439 | 84.5 | 3.61 % |
| Abbott India Ltd | 57,949 | 35.9 | 44.8 % |
| Gland Pharma Ltd | 49,333 | 43.1 | 15.1 % |
| Date | Client | Side | Qty | Price |
|---|---|---|---|---|
| 2026-09-30 | Neo Apex Share Broking Services Llp | SELL | 2,701,691 | 34.62 |
| 2026-09-30 | Neo Apex Share Broking Services Llp | BUY | 5,208,869 | 34.66 |
| 2026-09-29 | Neo Apex Share Broking Services Llp | SELL | 2,750,000 | 36.39 |
| 2026-09-29 | Neo Apex Share Broking Services Llp | BUY | 1,750,000 | 36.39 |
| Ex-date | Action | Factor |
|---|---|---|
| 2026-04-24 | Face Value Split (Sub-Division) - From Rs 10/- Per Share To Rs 2/- Per Share | 0.2000 |
| 2026-04-24 | Bonus 1:1 | 0.5000 |
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Long Term Additional Surveillance Measure (Long Term ASM): stage 1Scrip PE is greater than 50 (4 trailing quarters)